IL-1β signaling inhibitor (anti-IL-1R1)

An IL-1β signaling inhibitor (anti-IL-1R1) refers to a class of therapeutic agents, such as monoclonal antibodies or receptor antagonists, designed to target and block the interleukin-1 receptor type 1 (IL-1R1). By binding to IL-1R1, these inhibitors prevent the interaction of pro-inflammatory cytokines, specifically interleukin-1 beta (IL-1β) and interleukin-1 alpha (IL-1α), with the receptor. This blockade prevents the recruitment of the IL-1 receptor accessory protein (IL-1RAP) and halts downstream signaling cascades, such as the NF-κB and MAPK pathways, thereby suppressing the inflammatory response. These inhibitors are investigated for various inflammatory, autoimmune, and transplant-related conditions, including vascularized composite allograft (VCA) rejection, where IL-1β signaling in innate lymphoid cells (ILCs) plays a critical role in driving alloimmunity.

Other names

IL-1R1 antagonistIL1R1 antagonistIL 1R1 antagonistIL-1R1 inhibitorIL1R1 inhibitorIL 1R1 inhibitorIL-1β signaling inhibitoranti-IL-1R1 antibodyanti-IL1R1 antibodyanti-IL 1R1 antibodyanti-IL-1R1 monoclonal antibodyanti-IL1R1 monoclonal antibodyanti-IL 1R1 monoclonal antibody